Miyagi Children's Hospital

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Crohn's disease2 trials
• Ulcerative colitis2 trials
• Duchenne muscular dystrophy1 trial
• High blood pressure1 trial
• Psoriatic arthritis1 trial
• Spinal muscular atrophy1 trial

Phase

• Phase 36 trials
• Phase 1/21 trial

Status

• Active, not recruiting3 trials
• Completed3 trials
• Recruiting2 trials

Lead sponsor

• Eli Lilly and Company2 trials
• Janssen Research & Development, LLC2 trials
• Novartis Pharmaceuticals1 trial
• NS Pharma, Inc.1 trial
• Pfizer1 trial
• and 1 more

Running trials

• Active, not recruiting

  NS-050/NCNP-03 in Boys With DMD (Meteor50)

  NCT06053814· Phase 1/2· NS Pharma, Inc.· Source

• Recruiting

  A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

  NCT05509777· Phase 3· Eli Lilly and Company· Source

  Contact: Daiki Abukawa (principal investigator)

• Active, not recruiting

  Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

  NCT04624230· Phase 3· Pfizer· Source

• Recruiting

  A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

  NCT03773965· Phase 3· Eli Lilly and Company· Source

  Contact: Hiroaki Umebayashi (principal investigator)

• Recruiting

  Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

  NCT04174157· Novartis Pharmaceuticals· Source

  Contact: Novartis Gene Therapies

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease1 recruiting
• Psoriatic arthritis1 recruiting

Closed trials

• Completed

  A Study of TAK-536 in Children From 2 to Less Than 6 Years Old With High Blood Pressure

  NCT04668157· Phase 3· Takeda· Source

• Completed

  A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

  NCT04673357· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT04630028· Phase 3· Janssen Research & Development, LLC· Source